Imatinib is a tyrosine kinase inhibitor specific for abl (IC50 = 0.038 µM)1, PDGF-R (IC50 = 0.3 µM)1 and c-kit (IC50 = 0.1 µM)2. It is a clinically useful anti-cancer drug approved for the treatment of chronic myelogenous leukemia, gastrointestinal strom
* VAT and and shipping costs not included. Errors and price changes excepted